Description

Mefarmil (metformin hydrochloride) Coated Tablets 500 mg. №60

Ingredients

Active ingredient: Metformin hydrochloride 500 mg.

Dosage

Recommended dosage: The usual starting dose is 500 mg twice a day or 850 mg once a day with meals. Dosage adjustments should be made based on blood glucose levels.

Indications

Indicated for: Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients when dietary management and exercise alone do not result in adequate glycemic control.

Contraindications

Do not use if:

• Severe kidney disease
• Acute or chronic metabolic acidosis
• History of lactic acidosis

Directions

Administration: Swallow the tablets whole with a full glass of water. Do not crush or chew the tablets.

Scientific Evidence

Metformin hydrochloride, the active ingredient in Mefarmil tablets, is a first-line medication for the treatment of type 2 diabetes. It works by decreasing glucose production in the liver and improving insulin sensitivity in the body’s tissues. Several studies have demonstrated the efficacy of metformin in lowering blood glucose levels and reducing hemoglobin A1c levels.

Additional Information

Mefarmil tablets have a special coating that helps in reducing gastrointestinal side effects commonly associated with metformin. It is important to monitor kidney function regularly while taking this medication, as metformin can affect renal function. Consult your healthcare provider for personalized advice on dosage and usage.

Pharmacological Effects

Metformin hydrochloride acts primarily by suppressing glucose production in the liver. It also enhances insulin sensitivity in peripheral tissues, such as muscles, thereby increasing glucose uptake and utilization. Additionally, metformin has been shown to have beneficial effects on lipid metabolism, leading to improvements in lipid profiles in diabetic patients.

Clinical Trials and Comparative Effectiveness

Several clinical trials have compared the effectiveness of metformin with other antidiabetic medications. A study published in the New England Journal of Medicine found that metformin was associated with a lower risk of cardiovascular events and death compared to other commonly used diabetes drugs. This highlights the importance of metformin as a cornerstone in the management of type 2 diabetes.